Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized trial of extended temozolomide in glioblastoma
2014-000838-39Phase 2Completed
- Sponsor
- GEINO
- Start
- May 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of temozolomide in glioblastoma (GBM) (2 arms), sponsored by GEINO. Primary endpoints: Progression-free survival at 6 months and Overall progression-free survival. Started May 2014; status: completed.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2014-000838-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000838-39.